Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pityriasis rubra pilaris in children.

Dawn S Allison1, Rokea A El-Azhary, Stella D Calobrisi

  • 1Department of Dermatology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA.

Journal of the American Academy of Dermatology
|August 28, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Editorial: The push toward open access.

International journal of dermatology·2023
Same author

Palliative care utilization in calciphylaxis: a single-center retrospective review of 121 patients (1999-2016).

International journal of dermatology·2021
Same author

Retrospective analysis of 450 emergency department dermatology consultations: An analysis of in-person and teledermatology consultations from 2015 to 2019.

Journal of telemedicine and telecare·2021
Same author

Methods to Assess Disease Activity and Severity in Cutaneous Chronic Graft-versus-Host Disease: A Critical Literature Review.

Transplantation and cellular therapy·2021
Same author

Retrospective analysis of 578 inpatient dermatology consultations in hematology and hematopoietic stem cell transplant patients.

International journal of dermatology·2021
Same author

Disseminated intravascular coagulopathy: a complication of Stevens-Johnson syndrome/toxic epidermal necrolysis.

International journal of dermatology·2020
Same journal

Real-world experience with extended deucravacitinib-biologic combination therapy in refractory psoriasis and psoriatic arthritis.

Journal of the American Academy of Dermatology·2026
Same journal

Acute-phase Disease and Super-responder Status Predict Reduced Relapse Risk After Ritlecitinib Withdrawal in Alopecia Areata: A Prospective Real-World Study.

Journal of the American Academy of Dermatology·2026
Same journal

Response to Kvist-Hansen et al. 'Baseline monocytes ≥925/μL appear to represent a rare outlier phenotype rather than a generalizable predictor of adalimumab response in hidradenitis suppurativa.'

Journal of the American Academy of Dermatology·2026
Same journal

Navigating Difficult Conversations: Contraceptive Communication with Transgender and Gender Diverse Patients Starting Isotretinoin.

Journal of the American Academy of Dermatology·2026
Same journal

Ultrasound-Guided Hyaluronidase Administration with Remote Expert Guidance for Vascular Adverse Events after Filler Treatment.

Journal of the American Academy of Dermatology·2026
Same journal

Adalimumab Biosimilars and Access Barriers in Dermatology.

Journal of the American Academy of Dermatology·2026
See all related articles

Pityriasis rubra pilaris (PRP) in children, often the juvenile form, shows good response to retinoids like isotretinoin. Recurrence occurred in 17% of patients, suggesting retinoids as a key treatment for this rare condition.

Area of Science:

  • Dermatology
  • Pediatrics

Background:

  • Pityriasis rubra pilaris (PRP) is a rare pediatric skin condition.
  • Limited long-term data exists on pediatric PRP treatment and prognosis.

Purpose of the Study:

  • To review the clinical course and treatment of pediatric PRP cases.
  • To evaluate treatment efficacy and long-term outcomes in children with PRP.

Main Methods:

  • Retrospective review of 30 pediatric PRP patients (age ≤19) at Mayo Clinic (1975-1997).
  • Data collected via chart review and follow-up questionnaires.

Main Results:

  • Type III juvenile form was most common.
  • Isotretinoin showed the best response, with 5/6 patients achieving 90-100% clearing within 6 months.

Related Experiment Videos

  • Overall, 43% achieved complete resolution, 23% moderate, and 17% poor response. Recurrence was observed in 17% of those with complete clearing.

    • Conclusions:

    • Pediatric PRP is non-inherited, affects both sexes equally, and commonly presents as the juvenile form.
    • Systemic retinoids are recommended as a first-line treatment for pediatric PRP.
    • The recurrence rate of 17% highlights the need for ongoing monitoring and management.